We found that the GLP‐1 receptor (GLP‐1R) agonist Exendin‐4 improves Aβ31‐35‐induced circadian rhythm disorders.5 However, the study showed that during hyperglycemia, the activation of the GLP‐1R could induce acute blood glucose‐lowering effects.7 Therefore, it is essential to identify safer and more effective treatments. The gene discussed is GLP1R; the disease is Hyperglycemia.